Feeds:
Posts
Comments

Archive for the ‘LPBI Group, e-Scientific Media, DFP, R&D-M3DP, R&D-Drug Discovery, US Patents: SOPs and Team Management’ Category

LPBI Group announces 5th Academic INTERNSHIP as a Verifiable Certificate in Financial Modeling & Econometrics as One Semester or as One Year Program open to Undergraduate and MBA students

Author: Aviva Lev-Ari, PhD, RN

5th Internship in FINANCE:

Open to College students 3rd year or MBA students that need a Project to submit like a Capstone or a Thesis that involve INDEPENDENT under supervision & mentorship CREATIVE research – Diving with a Mentor into dealing with unresolved problems in the topic of Intellectual Property Asset Valuation – rough waters, daring to do so by thinking out of the Box !!!!!!!

  • No existing solution fits our problem
  • We need to device a solution a new
  • Aviva will be the guide

Candidate had academic courses in college on Statistics, Economics, Accounting, Finance, Operations Research, Probability

  • Candidate masters FORMULAS in Excel
  • Candidate can code a computer program and use statistical packages
  • Candidate is savvy and agile, enjoys experiments with data and get needs experience with BIG DATA to become a Data Scientist in graduate School
  • Able to go to literature with guidance and fetch and use what was found in literature to apply and further the research agenda

As an example:

A perspective on the valuation of companies with significant Intangible assets, like LPBI is presented and analyzed in the following curation on the Intangible Asset of Firm’s Reputation. In the case of LPBI, the intangible assets it possesses are key determinants of its reputation and digital reputation on the Internet as is the case in the Media World.

The Digital Age Gave Rise to New Definitions – New Benchmarks were born on the World Wide Web for the Intangible Asset of Firm’s Reputation: Pay a Premium for buying e-Reputation

PROJECT DEFINITION: Develop a Valuation Model for an Intellectual Property Portfolio of Digital Assets in Pharmaceutical Media that includes Intangible assets as well.

Under development

· IP Valuation Model per IP asset class is needed to be compared with Master_Financials and to supplement it

· Pricing Model and Product Mix Models for the digital products to be generated by the process of Text Analysis with NLP are using a Product Price List already developed.

· The scenarios for a Probabilistic Product Mix for the B2B sector are work-in-progress. 

· Scenarios of Product Mix for $500,000 B2B engagements with NLP scaling up with NLP Alliances. The Alliances are the Labor component and LPBI is Materials as 25% of the contract price, on top of total, to be paid by the B2B customer as materials in use of the engagement.

· B2C on Blockchain will use the Price List for all Digital Products of LPBI 1.0 and LPBI 2.0 – pay per use

· Product list will be in use for B2C vs Engagements to be used for B2B


• LPBI’s Valuation of Intellectual Property does not correspond to the Discount Rate of Net Present Value (NPV) which is the difference between the present value of cash inflows and the present value of cash outflows over a period of time. NPV is used in capital budgeting and investment planning to analyze the profitability of a projected investment or project. It does not correspond because nor the innovation type or the rate of innovations are predictable by any set of assumptions that would under lie such models.

• LPBI’s Valuation of Intellectual Property does not correspond to its revenues derived from Royalties on Books. The Pay per View as practiced by Page Download is hindering books sales and Royalties are determined by Amazon.com have never been in favor of Authors. Our page download equate to 64 books not sold because of the option of Pay per View.

• LPBI’s Intellectual Property is a factor of production as input to the Drug discovery process, see Mission 4, below or Claims adjudication, see Mission 1, below.

• LPBI’s Intellectual Property is a critical component in information syndication of Pharmaceutical Media, see Mission 3, below

• LPBI’s Intellectual Property has the potential to become an input into the development process of software application development for Pharma and Biotech by IT Organizations like Apple Health, Intel Health, Google’s Verily, SAP, Oracle and IBM Watson.

• LPBI’s Intellectual Property is a formidable candidate for a Holding company with existing Online health publishing, Health Care Media, Web-Health and Health Information Markets, i.e., KKR

• LPBI’s Intellectual Property is an attractive candidate for the EDTech industry supplying education content for the the Global and very fast growing emerging Online Education sector including all tiers of the Academic ecosystem   getting blurred boundaries such as Ivy League institutions offering Certificates along the side of academic degrees. Certificates are coveted by employers. LPBI is running a One year Academic Certificate in NLP for Medical Text Analysis in Mission #1 and in Synthetic Biology Software in Mission #4.

LPBI Opportunities Map is comprehensive and includes 12 Economic Segments include the follwoing: Holding Companies; Investment Bankers and Private Equity; Information Technology Companies – Health Care; Scientific Publishers; Big Pharma; Internet Health Care Media & Digital Health; Online Education; Health Insurance Companies & HMOs; Medical and Pharma Associations; Medical Education; Information Syndicators; Global Biotech & Pharmaceutical Conference Organizer and CRO & CRA.

SOURCE: Opportunities Map in the Acquisition Arena

OTHER FOUR INTERNSHIPS at LPBI Group

LPBI Group runs FOUR ACADEMIC INTERNSHIPS as verifiable Certificate Programs a One Year long or a One Semester long: Volunteer base – you earn TRAINING and a CERTIFICATE Tuition FREE

LPBI has Students and their education goals in mind:

  • We Offer esteemed Affiliation, Mentorship by Scientists
  • NEW skills development in NLP, ML, AI applications to Medical Text Analysis
  • Skills in Synthetic Biology for Drug Discovery
  • References and Resume paragraph on accomplishments and goals during the INTERNSHIP
  • Opportunity to contribute to Publications and Podcasting
  • Explorations of opportunities in Life Sciences in the US

These are the FOUR ACADEMIC INTERNSHIPS as verifiable Certificate Programs One year or One semester: Volunteer base

  1. NLP – Medical Text Analysis https://pharmaceuticalintelligence.com/2021-medical-text-analysis-nlp/
  2. Synthetic Biology in Drug Discovery targeting Galectins https://pharmaceuticalintelligence.com/synthetic-biology-in-drug-discovery/
  3. IT Projects and Administration of IP Asset Classes. we developed a Plan for SOPs for LPBI Group’s IT & Data Science Management Projects

Informations technology & systems of LPBI: Journal, Books, e-Proceedings & Tweet Collections and GALLERY of +6,200 Biological Images. All the platforms: Authoring, publishing and portals. Business analytics for Internet platforms presence: Twitter Analytics +1,100 followers of two handles and LinkedIn ~8,000 1st degree connections of LPBI’s Founder, including +500 CEOs.

4. BLOCKCHAIN Architecture Design: Interface to NLP. The powerful aspect is hydrating a knowledge graph with NLP inferences so that they can be used for DISCOVERY. Storing those inferences on a blockchain have the value of committing the NLP inferences to a blockchain for purposes of provenance. However, the very important part is The INFRASTRUCTURE behind BurstIQ which is NOT JUST A BLOCKCHAIN. NLP-Blockchain IT Infrastructure is needed. The NLP inferences are part of a knowledge graph database In BurstIQ case is a LifeGraph – the larger architecture of the system functionality [the voice of Erich G., Chief Architect, LPBI Blockchain Mission #2].

For immediate consideration: Submit CV as MS Word file to:

AvivaLev-Ari@alum.berkeley.edu

617-775-0451

Boston, MA, USA

Read Full Post »

WORKFLOW for a Ten-Steps Medical Text Analysis Operation using NLP on LPBI Medical and Life Sciences Content

Author: Aviva Lev-Ari, PhD, RN

  • All INTERNS will work 50% on NLP and 50% on Synthetic Biology
  • Training will be offered
  • Protocol will be developed 
  • Software applications will be selected.
  • Mid September we will have an Internal Meeting on Mission #2, LPBI India before the Meeting with Dr. Nir
  • All Interns need to complete at least ½ an e-Book Ten-Step Workflow Protocol for NLP before starting the Synthetic Biology SW Training
  • This is the Ten-Step WORKFLOW Protocol for Medical Text Analysis using NLP at LPBI:
  • https://pharmaceuticalintelligence.com/2021/07/15/workflow-for-a-ten-steps-medical-text-analysis-operation-using-nlp-on-lpbi-medical-and-life-sciences-content/
  • Each INTERN Completing the 50% assignment on NLP will need to submit this table for his/hers NLP Book Assignment with a Check off mark for each article in each Chapter in the Book the intern was assigned for
  • This Table filled in serves as INPUT for QA of the work of the INTERN. Verification is needed for Internship completion for Certification purposes
NLPStep 1Step 2Step 3Step 4Step 5Step 6Step 7Step 8Step 9Step 10
Chapter 1, Article 1          
Chapter 1, Article n          
Chapter 2 Article 1          
Chapter 2, Article n          
Chapter 3, Article 1          
Chapter 3, Article n          
Chapter 4 Article 1          
Chapter 4, Article n          
Chapter 5, Article 1          
Chapter 5, Article n          
Chapter n Article 1          
Chapter n Article n          

Table Source :

Author: Aviva Lev-Ari, PhD, RN, 7/23/2021

This Table is the supporting evidence for:

LPBI’s WORKFLOW for a Ten-Steps Medical Text Analysis Operation using NLP on

LPBI Medical and Life Sciences Content

STEP 1: Domain Knowledge Expert Specifies the selection criteria for a Collection of Articles:

  1. Curated & authored articles vs scientific reports
  2. All articles in a Chapter in a book, [N = 1,2,3,  ..,18]
  3. Selection of articles within a Research Category [N = 1,2,3,  ..,730]
  4. Selection of articles within several Research Categories

STEP 2:    Create .TXT file for each article in the collection

STEP 3:    Create one MERGED .TXT File for all the articles in the collection

THIS ARE THE INSTRUCTIONS FOR PERFORMANCE OF 6 ALGORITHMS FOR NLP – INSTRUCTIONS ARE AUTHORED BY MADISON DAVIS. CODE FOR BAR DIAGRAM PLOTS, HYPERGRAPH VERSION 1 AND TREE DIAGRAM PLOTS REPRESENT CODE WRITTEN BY YASH CHOUDHARY

FOR AN EXAMPLE OF A COMPLETED PowerPoint Presentation, go to


http://powerpoint linked here (https://docs.google.com/presentation/d/14qbyKh-HFBTAHvgwOaJTIOfDc59rarQB149ICRIgitk/edit#slide=id.gea73ad4e78_0_31)

INSTRUCTIONS TO ALL INTERNS on how to run six algorithms: 25 KeyWord Extraction, Hypergraphs, Tree Diagrams (all 3 of which are Yash’s code), Bar Diagrams, and Word Clouds.

The link here https://docs.google.com/document/d/10U_O36zeHQgq6MGU_Nsbz4FYXjKkbSWdCXkJALp-Ymk/edit#heading=h.k9zii87j8i61 contains the finalized Instructions for the Interns. 

It covers six algorithms: 25 KeyWord Extraction, Hypergraphs, Tree Diagrams (all 3 of which are Yash’s code), Bar Diagrams, and Word Clouds.  Some of the algorithms require you to have a title in the diagram, and I highlighted the parts of the code where the Interns need to change the text so that the title reflects the work/textbook that they are doing.

STEP 4:    Use WordItOut.com and .TXT file per article to generated One WordCloud per article

4.1    Edit Graph – remove connective words

4.2    Upload WordClouds to the Media Gallery and record Article title as Legend and Source for the graph, add your name as image producer and date

4.3    Insert World Cloud in the Article following the Author/Curator’s name

4.4    Place WordCloud in a one PowerPoint Presentation for the entire Article Collection

STEP 5:    Use .TXT file per article to create a Bar Diagram for the word frequencies in the article

5.1    Edit Bar Diagram and remove connective words

5.2    Place each Bar Diagram in the PowerPoint Presentation for the article collection

STEP 6:    Use the one MERGED .TXT file to create ONE Hyper-graph for the entire article collection

6.1    Edit Hyper-graph

6.2    Place Hyper-graph in the PowerPoint presentation

STEP 7:    Use the one MERGED .TXT file to create ONE Tree Diagram for the entire article collection

6.1    Edit Tree Diagram

6.2    Place Tree Diagram in the PowerPoint presentation

STEP 8:    Transfer all visualization in PowerPoint into a Domain Knowledge Expert Interpretation Folder

STEP 9:    The highest value added step:

Domain Knowledge Expert generates a .DOCX file with his expert interpretation of all the Insights drawn from the visualization artifacts generated by NLP, ML, AI when all the insights are put together for analysis and synthesis.

9.1    What are the clinical implications for patient treatment

9.2    What are the clinical insights for drug discovery for Big Pharma?

9.4    Are there clues for risk adjustment and policy writing tips for health care insurers?

9.5    Store the Expert interpretation into the Interpretation Folder

STEP 10:  Transfer copy of Interpretations files for Translation into Foreign Languages: Spanish, Japanese, Russian into Folders with Language Name

STEP 11: Under Construction: Enrichment of the original content with External Repositories

Read Full Post »

Author: Aviva Lev-Ari, PhD, RN

We need to create a Folder on DropBox: named

  • SOPs for LPBI IT & Data Science Management

Nested Folders:

  1. Data Extraction of Article Views [Srini & Abhisar – Managers]
  2. How to get a DropBox Account [Srini & Abhisar – Managers]
  3. How to start a New Website connected to PharmaceuticalIntelligence.com [Srini & Abhisar – Managers]
  • Spanish BioMed e-Series – New website
  • LPBI India – New website
  • 2.0 LPBI, 2021-2025 -– New website
  1. Six Requirements for all LPBI members [Aviva – Manager] – Onboarding Process
  2. Posting Styles on PharmaceuticalIntelligence.com
  • Reporter’s role
  • Curator’s role
  • Author’s role
  • Editors’s role
  1. How to Convert Text to Audio Podcast [Ethan – Manager]
  2. Twitter Analytics for @pharma_BI @AVIVA1950 [Ethan – Manager]

Read Full Post »

Identification of the Top Ranked articles by Views since date of publication

Data extraction by Srinivas Sriram and Abhisar Anand, 2021 Summer Interns 

 
TitleViews through Method 1
Home page / Archives765,595
Is the Warburg Effect the Cause or the Effect of Cancer: A 21st Century View?17,365
Recent comprehensive review on the role of ultrasound in breast cancer management16,246
Paclitaxel vs Abraxane (albumin-bound paclitaxel)15,227
Do Novel Anticoagulants Affect the PT/INR? The Cases of XARELTO (rivaroxaban) and PRADAXA (dabigatran)14,370
Apixaban (Eliquis): Mechanism of Action, Drug Comparison and Additional Indications9,678
Clinical Indications for Use of Inhaled Nitric Oxide (iNO) in the Adult Patient Market: Clinical Outcomes after Use, Therapy Demand and Cost of Care9,111
Our TEAM6,740
Mesothelin: An early detection biomarker for cancer (By Jack Andraka)6,623
Interaction of enzymes and hormones6,017
Pyrroloquinoline quinone (PQQ) – an unproved supplement5,956
 Recorded as of July 2nd

Read Full Post »

This content is password protected. To view it please enter your password below:

Read Full Post »

2.0 LPBI is a Very Unique Organization

Author: Aviva Lev-Ari, PhD, RN, Founder of 1.0 LPBI and 2.0 LPBI, April 2012 to Present

UPDATED on 9/17/2021

LPBI is seeking strategic avenues that are DIFFERENT than

  • Private Debt
  • Direct Public Offering

LPBI Group’s situation in 2021 is CLEAR

LPBI is Debt Free and needs to Sell Outright its Portfolio of Intellectual Property Assets:

1.0 LPBI IP Asset Classes I to X, as describe in  https://pharmaceuticalintelligence.com/2019-vista/

2.0 LPBI IP Asset Classes to be created in 2021 – 2025 – Work-in-Progress on XI, XII, XIII, as described, below

  • IP Asset Class XI – the outcomes of Missions #1 – NLP on Journal Articles, Books, E-Proceedings, Biological Images Text Legend
  • IP Asset Class XII – the outcomes of Missions #3 – New Genre of Scientific Books: Spanish, Audio, NLP Results
  • IP Asset Class XIII – the outcomes of Missions #4 – Drug Discovery with Synthetic Biology Software

Design of Blockchain Content Monetization Platform is in earnest on two fronts:

  • Internal: Erich and LMU CS Department using Fluree open source
  • External: Alliance with BurstIQ, Denver if deployment is needed in 3 months

Deep Learning NLP for Text Analysis: Journal articles (N=6,085), 18 e-Books, 100 e-Proceedings, +6,200 Biological Images with text legend

  • Internal: Wolfram Deep Learning NLP
  • External: Linguamatics/IQVIA, if Scaling up from Proof-of-Concept to all Books called by a Joint Customer [Insurer in UT is Aviva’s Contact]

LPBI Team members understand that the following two strategies are not the appropriate strategies for us to undertake. These strategies are:

  • Private Debt

No person on LPBI’s Team would sign a LOAN and commit to pay it back. Even if we incorporate – the Team members will not take such a responsibility.

  • Direct Public Offering (DPO)

DPO – most likely is not suitable for any IP Portfolio. These asset classes, their value has a very strong INTANGIBLE component, they are Intellectual Property not Real estate or tangible assets. Thus, can’t be treated as securities.

Therefore, LPBI’s Founder and Board are seeking an Acquirer that will

  • Acquire the assets
  • Incorporate the business and
  • Bring a new Team
  • In this scenario, the new business may be suitable for Private Debt ????
  • LPBI’s Team members are not suitable to raise debt

UPDATED on 8/11/2021

Potential opportunities for ownership transfer need to consider three components:

(a) 1.0 LPBI: the Portfolio of TEN Intellectual Property (IP) Asset Classes developed in 2012-2020

(b) 2.0 LPBI: FOUR Missions for 2021-2025, and

(c) the TEAM in the USA and in India

An inclusive plan for three Exit Options was developed:

Exit Option #1:

  • Outright Sale of 10 IP assets

Exit Option #2:

  • Turnaround Version 1: A [Outright Sale of 10 IP assets] + B [Inorganic] EXTERNAL management and EXTERNAL ownership for 2.0 strategy, make use of the already in place and which represents the economic potential of 1.0 LPBI when it is developed by new technologies beyond the e-Scientific Publishing art. Unleashing this potential for generation of new digital products is boundless, it includes the following five alliances, but is not limited to only these listed, below:
  1. Alliances in Medical Text Analysis using NLP, Proof-of-Concept was tested. It will be followed by scaling up to all content of following four IP asset classes to benefit from Text Analysis with Machine Learning algorithms, i.e., in text format (Journal articles, e-Books, e-Proceedings and Gallery of Biological Images with text legends)
  2. Alliance in Blockchain Transactions Network for B2B & B2C enabling Content Monetization. Status: design phase
  3. Alliance for English Book translation to Spanish. Status: completed, all 18 books (Cover Page and eTOCs).
  4. Alliances in Content promotion in Spanish speaking countries. Status: Plan developed and
  5. Alliance in Synthetic Biology Software for targeted therapeutics in Drug Discovery.Status: ongoing

AND the Team of Experts in the US and in India.

Exit Option #3:

  • Turnaround Version 2: Organic – “Equity” Sharing Buyout

  1. Buying out Aviva’s LION’s share AND
  2. Buying out Dr. Larry’s share  AND
  3. Continue 2.0 LPBI by LPBI INTERNAL management [SJW & JFM] AND NEW EXTERNAL Ownership.
  4. The Right of First Refusal is offered INTERNALLY to 1.0 LPBI member(s) to take the helm of 2.0 LPBI to execute on Missions #1, #2, #3, #4

AND the Team of Experts in the US and in India

2.0 LPBI Strategy for 2021-2025

Smart use of customizable software in conjunction with

1.0 LPBI IP assets and Team’s competencies:

1.0 LPBI and 2.0 LPBI

  1. Use of the existing content to create new Digital products
  2. Train Biologists in NLP Software for Mission #1: Text Analysis with NLP, and
  3. Train Biologists in Synthetic Biology Software for Mission #4: Synthetics Biology Software in drug discovery
  4. 2.0 LPBI via our five Academic INTERNSHIPS means training MASTERS LEVEL and PostDoc BIOLOGISTS and Computer Scientists to use software for: (a) Mission #1 and (b) Mission #4
  5. Use Blockchain architecture for content monetization of the following IP assets:
  • all 1.0 LPBI digital products
  • all 2.0 LPBI digital products created in Mission #1, #3 and #4 described, below

The Four Missions of 2.0 LPBI Strategy for 2021-2025

Mission #1:

Natural Language Processing (NLP) – Team in USA & India – Medical Text Analysis with NLP – on LPBI 3.3 Giga Bytes of Content. Two NLP types:

(a) Statistical NLP and

(b) Semantic NLP with Deep Learning by Machine Learning algorithms using Wolfram Language for Biological Sciences

https://pharmaceuticalintelligence.com/2021-medical-text-analysis-nlp/

In Mission #1: Using Machine Learning (ML) algorithms for Text Analysis of our 3.3 Giga Bytes of English Text

Statistical Natural Language Processing (NLP) is yielding:

  • WordClouds and Bar Diagrams for each article, and

Deep Learning (DL) for Semantic Analysis of the Text will yield:

  • Hyper-graphs for collections of articles using knowledge graphs in knowledge graph databases.
  • Tree Diagrams for collection of articles

Domain knowledge experts will perform Interpretation of the visualization results generated by the Statistical NLP and the Semantic NLP with Deep Learning.

  • The Interpretation text will be in English and in foreign languages and in Audio Podcasts per language

Mission #2:

Blockchain IT and NLP Processing API generating NLP visualization products using Knowledge Graphs stored in Graph Databases on the Blockchain IT to be design for Content monetization use with unique infrastructures for  B2B and B2C.

1.0 LPBI was Open Access and Equity Sharing e-Scientific Publisher using a Cloud-based Authoring platform

2.0 LPBI will be focusing on Content Monetization and user of multiple software technologies unique for each of the its Missions: #1, #2, #3, #4.

  • The Open Access status will change when we will migrate all the four classes of content relevant for Text Analysis with NLP to the Blockchain Transactions Network. IT platform is currently under design.

Scenario from the End User Perspective

  • Interested parties posing queries to the system (B2C)
  • System responds by triggering a Recommendation Engine Response (RER) that will fetch: top articles by views
  • If the article was published in a book THEN the selected Article in the context of all articles in same chapter in the book it was featured will form the article collection for NLP performance.
  • If article not in a book then in the context of other articles in same categories of research, ones selected by the recommendation engine and ranked by views.
  • Biological images in these articles will be displayed
  • NLP results in visual graphics will be displayed
  • Major Data Science procedures in the back-end are using graph databases for on the Fly generation of NLP results not performed before, thus, not stored in the knowledge graph databases
  • Domain Knowledge Expert interpretation of the graphics available for selection in several Foreign languages presented in the front-end.
  • System invokes Blockchain features embedded per LPBI specifications into the API layer(s) of the Blockchain Transactions Network for its cardinal technology features: i.e.,
  1. Permissions
  2. Immutable LEDGER
  3. Smart Contracts
  4. Cyber security of IP assets in blocks

Full feature operations of the Blockchain platform will enable

  • B2C – Digital Store on a Healthcare Digital Marketplace
  • B2B – Installation at Big Pharma, Healthcare Insurers and CRO

https://pharmaceuticalintelligence.com/blockchain-transactions-network/

In Mission #2: The Transactions-enabled blockchain platform for Content Monetization of IP assets embodies the  development of a Blockchain information technology infrastructure that is transactions-enabled allowing payments for content digital products. On the blockchain we will store all the following Digital products.

All newly produced digital products by NLP serve as a compelling justification for the selection of Blockchain Transactions Network architecture as our IS/IT platform selected among other IT alternatives, using Knowledge Graph database the schema of which is derived from the Journal Ontology of 730 categories of research.

1.0 LPBI Four IP Asset Classes for Application of NLP – Original Products

IP Asset Class I: Journal articles +6,085

IP Asset Class II: electronic Books in Medicine. The five specialties in medicine are:

Series A: Cardiovascular Diseases: six volumes,

Series B: Genomics: two volumes,

Series C: Cancer and Oncology: two volumes,

Series D: Immunology: Metabolomics, Genomic Endocrinology and Infectious diseases: four volumes, and

Series E: Precision Medicine: four volumes

2a.     18 e-books in English on Amazon.com

2b.     18 Bi-Lingual electronic Table of Contents (eTOCs): Spanish & English

  • From IP Asset II: BioMed e-Books: All digital products

2.0 LPBI – NLP on Four IP Asset Classes – All results of NLP on the Original Products

2c.     18 e-Books – NLP visualization products [WordClouds, Bar Diagrams, Hyper-graphs, Tree Diagrams]

  • From IP Asset Class I: Journal Articles and from II: BioMed e-Books

2d.     18 e-Books Domain Knowledge Expert written Interpretations of the NLP visualization results: Spanish & English

  • From IP Asset Class I: Journal Articles and from II: BioMed e-Books

2e.     For 18 books all audio Podcasts in Spanish & English – selective content, i.e., Editorials: Preface, Introduction, Summary, Epilogues as English podcasts.

  • From IP Asset II: BioMed e-Books: All digital products

2f.     For each e-Series, A,B,C,D,E we plan to publish a volume containing the Bi-Lingual Spanish-English electronic Table of Contents in each e-Series for all the e-Books in the e-Series – an additional 5 Bi-Lingual e-Books.

  • From IP Asset II: BioMed e-Books: All digital products

IP Asset Class III:      e-Proceedings and Tweet Collections: 100 volumes

IP Asset Class V:       Gallery of Biological Images 6,200 to grow given that the NLP yields 10 graphs 📊 per article

2.0 LPBI all Products of NLP, see Yields for Mission #1, above

PLUS

Pipeline Products, 2021-2025 beyond 1.0 Ten IP Asset Classes:

New IP Asset Classes are: XI, XII, XIII

IP Asset Class XI (Queries yielding results on the Fly) – ending up in Blockchain storage available for monetization as a new product

  • New Digital Products as a result of Discovery 💡 of new digital products derived from and created from the new queries by users to be generated on the fly not in existence in the knowledge graph database

In addition, all new Digital Products of Mission #3 and Mission #4

IP Asset Class XII (Mission #3) – ending up in Blockchain storage available for monetization transactions as new products

  • All digital products of Mission #3, below: New Genre of Scientific Books N =18, see book architecture, below,

IP Asset Class XIII (Mission #4) – ending up in Blockchain storage available for monetization transactions as new products

  • All digital products of Mission #4, below: New therapeutics molecules generated for 12 Galectins by Synthetic Biology software

Mission #3:

New GENRE of Multimedia Scientific Books: These 18 LPBI e-Books will be the first on the Medical Books Market to contain Text Analysis with NLP of the original e-Books. BioMed e-Books – Book Republishing in new GENRE – Bi-Lingual and Multimedia Audio Podcast for Books in the 18-e-Books in five e-Series: A,B,C,D,E . The New book architecture for each Book:

  • Part A: Spanish and English electronic Table of Contents in Text and in Audio Podcast.
  • Part B: NLP & Expert Interpretation of the visualizations in Text and Podcast: English and Spanish,NLP results for the content of the e-Book
    • Hyper-graphs for each Chapter
    • Domain Knowledge Expert Interpretation of all NLP results:

    TO BE CREATED – English Text and Spanish Text

    TO BE CREATED – English Audio Podcast and Spanish Audio Podcast

  • Part C: Editorial of original book (Preface, Volume Introduction, Volume Summary and Epilogue) – English Audio Podcast of existing Text.

https://pharmaceuticalintelligence.com/2021/07/24/proposal-for-new-e-book-architecture-combining-a-bi-lingual-etocs-english-spanish-with-nlps-results-of-medical-text-analysis-series-b-genomics-volume-1-2-and-series-c-cancer-volume-1/

Mission #4:

Synthetic Biology Software for Drug Discovery 💡 targeting Galectins.

  • See all the details in the link, below 

https://pharmaceuticalintelligence.com/synthetic-biology-in-drug-discovery/

LPBI’s VALUATION

LPBI’s VALUATION is the stream of INNOVATIONS to date achieved while staying DEBT free: We need an unconventional approach to valuation and to prospecting for a Merger and Acquisition for LPBI.

Being debt free and loaded on Intellectual Property place LPBI Group in a special position for Transfer of Ownership. Only a 3rd party who value Intellectual Property in Pharmaceutical Media belongs to the discussion.
The accomplishments of the last almost ten years 2012 -2020, are described, below.
PERSPECTIVE

Leaders in Pharmaceutical Business Intelligence aka LPBI is a Registered Domain Name on WordPress.com.

  • LPBI is a Cloud-based Internet Business.

LPBI is not a manufacturing plant or a brick and mortar chain with Assets and Liabilities and AMORTIZATION and the discount rate that is chosen for the present value calculation (NPV) – these methods are terms not used for

  1. the valuation of Intellectual Property portfolios and not used for
  2. MEDIA ventures deriving prominence from digital reputation of intangible assets

Our Content is updated daily and it grows daily. We enjoy +20,000 e-Readers a month and the planned Medical Text Analysis with machine learning (Natural Language Processing) will general ~10 new digital artifacts per each existing article [N = +6,080].

• LPBI’s Valuation of Intellectual Property does not correspond to the Discount Rate of Net Present Value (NPV) which is the difference between the present value of cash inflows and the present value of cash outflows over a period of time. NPV is used in capital budgeting and investment planning to analyze the profitability of a projected investment or project. It does not correspond because nor the innovation type or the rate of innovations are predictable by any set of assumptions that would under lie such models.

• LPBI’s Valuation of Intellectual Property does not correspond to its revenues derived from Royalties on Books. The Pay per View as practiced by Page Download is hindering books sales and Royalties are determined by Amazon.com they have never been in favor of Authors. Our page download equate to 64 books not sold because of the option of Pay per View.

• LPBI’s Intellectual Property is a factor of production as input to the Drug discovery process, see Mission 4, below or to Claims adjudication, see Mission 1, below.

• LPBI’s Intellectual Property is a critical component in information syndication of Pharmaceutical Media, see Mission 3, below

• LPBI’s Intellectual Property has the potential to become an input into the development process of software application development for Pharma and Biotech by IT Organizations like Apple Health, Intel Health, Google’s Verily, SAP, Oracle and IBM Watson.
• LPBI’s Intellectual Property is a formidable candidate for a Holding company with existing Online health publishing, Health Care Media, Web-Health and Health Information Markets, i.e., KKR
• LPBI’s Intellectual Property is an attractive candidate for the EDTech industry supplying education content for the Global and very fast growing emerging Online Education sector including all tiers of the Academic ecosystem as boundaries are getting blurred. Ivy League institutions offering Certificates along the side of Academic degrees. Certificates are coveted by employers. LPBI is running a One year Academic Certificate in NLP for Medical Text Analysis in Mission #1 and another one in Synthetic Biology Software in Mission #4.
  • LPBI Opportunities Map is comprehensive and includes 12 Economic Segments include the follwoing: Holding Companies; Investment Bankers and Private Equity; Information Technology Companies – Health Care; Scientific Publishers; Big Pharma; Internet Health Care Media & Digital Health; Online Education; Health Insurance Companies & HMOs; Medical and Pharma Associations; Medical Education; Information Syndicators; Global Biotech & Pharmaceutical Conference Organizer and CRO & CRA.

A perspective on the valuation of companies with significant Intangible assets, like LPBI is presented and analyzed in the following curation on the Intangible Asset of Firm’s Reputation. In the case of LPBI, the intangible assets it possesses are key determinants of its reputation and digital reputation on the Internet as is the case in the Media World.

The Digital Age Gave Rise to New Definitions – New Benchmarks were born on the World Wide Web for the Intangible Asset of Firm’s Reputation: Pay a Premium for buying e-Reputation

  • e-Reputation: LPBI’s Twitter handles are followed by the most esteemed Institutions, see Here and Here.

A stream of Ten INNOVATIONS in the Life of LPBI since

inception in 2012 to 2021

  1. 4/2012 – LPBI was the Launcher of a novel Scientific Curation Methodology for scientific findings in published primary research in the Global e-Scientific Publishing industry https://pharmaceuticalintelligence.com/
  • As late as 2016, no big publisher, not even one, i.e., Elsevier, John Wiley had curation-based publications: Journals, Books, e-Proceedings or Gallery of thousands of Biological Images as an IP asset class
  • At LPBI, Curation of scientific findings was performed in +6,000 articles with +2MM e-Views by Global e-Readers
  1. 6/2013 – LPBI was the Publisher of the 1st e-book in Medicine in Kindle Store on the Life Sciences & Medicine Shelf – Upload to this shelf by Amazon.com
  1. 2/2021 – Completion of the 18 volumes, BioMed e-Series in five Specialties in Medicine: each article in each volume is a curation-based publication.
  1. On Amazon.com on 7/2021 – LPBI’s e-books in Medicine enjoy +128,100 PAGE DOWNLOADS – the ONE and ONLY publisher in that range of page downloads. The record is the equivalent of 64 books at an average of 2,000 pages a volume !!!! LPBI smallest book is 1,000 pages and its biggest is +3,700 pages
  1. LPBI launched its Natural Language Processing (NLP) Practice in 1/2020 as Mission #1. NLP is one method of Machine Learning (ML). ML is a family of methods in Artificial Intelligence (AI) which is a field in the Computer Science Academic discipline since the early 60s.

In 4/2021 Linguamatics/IQVIA performed NLP on LPBI’s 33 articles and 20 Biological Images. RESULTS:  +670 entity relations DISCOVERED by Linguamatics and unknown to Pharma and to Insurers, entity relations between:

  • Gene-Disease
  • Gene-Drug
  • Disease-Drug

These results were jointly presented to a Healthcare Insurer, SLC, UT on 7/13/2021, forthcoming meeting in 9/2021.

  1. LPBI and BurstIQ are architecting NOW the first Natural Language Processing – Blockchain Information Technology infrastructure in existence, This statement is TRUE.
  • Updated on 7/28/2021: Fluree Flur.ee, the Web3 Data Platform Open source semantic graph database & LeadSemantics.com presented their solution for NLP and Blockchain on 7/28/2021. Erich G. was lured as Chief architect for LPBI’s Mission #2: NLP & Blockchain
  • Linguamatics, the leader in NLP did not hear of Blockchain and BurstIQ did not have a request for NLP – LPBI PUT THESE TWO TECHNOLOGIES AND PARTIES TOGETHER

LPBI workflow overview

IMAGE SOURCE: BurstIQ image for LPBI

  1. On 7/19/2021 – LPBI had launched LPBI India for Synthetic Biology Software for Drug Discovery targeting Galectins – Collaboration with Dr. Raphael Nir, President and CSO, SBH Sciences, Inc., Natick, MA
  1. On 7/25/2021 – LPBI announced that it will have the NEWLY to be published BioMed e-Books As Mission #3:

A NEW Publishing GENRE of SCIENTIFIC BOOKS

    • Bi-Lingual electronic Table Of Contents (eTOCs), English & Spanish with Montero Language Services, Madrid as the Translator of eighteen Books’ Cover Pages and the 18 books electronic Table of Contents.
    • The Content promotion in the Spanish speaking Countries with GTO, Madrid as AD Agency.
    • NLPs results of Medical Text Analysis with domain knowledge expert Interpretations in Foreign Languages and in Audio: in Spanish and in other languages, forthcoming
    • Original English Book – Only Editorials (Preface, Introductions, Summaries and Epilogue) because the Bi-Lingual part has the eTOCs of the e-Book
    • This is a new genre and a new architecture of 18 MULTIMEDIA SCIENTIFIC e-Books with (a) NLP results of the Medical Text analysis with machine learning, (b) Expert Interpretation of the Visualization Results. Bi-Lingual Podcasts: (c) eTOCs and (d) Bi-Lingual Expert Interpretation in English and Spanish Text and audio Podcasts, and (e) Books’ Editorials in English Audio Podcast

Content promotion proposal by GTO, Madrid

20210622_lpbi_pipeline_gto_europe-1

IMAGE SOURCE: Rendition by GTO, Madrid of BurstIQ Image, above

  1. The Content Monetization effort includes the Price List for LPBI 1.0 digital products and of LPBI 2.0 – NLP Products

Under development

  • IP Valuation Model per IP asset class is needed to be compared with Master_Financials and to supplement it
  • Pricing Model and Product Mix Models for the digital products to be generated by the process of Text Analysis with NLP are using a Product Price List already developed.
  • The scenarios for a Probabilistic Product Mix for the B2B sector are work-in-progress. Scenarios of Product Mix for $500,000 B2B engagements with NLP scaling up with NLP Alliances. The Alliances are the Labor component and LPBI represent Materials (Content) as 25% of the contract price, on top of total, to be paid by the B2B customer as materials in use for the engagement.
  • B2C Customers on Blockchain will use the Price List for all Digital Products of LPBI 1.0 and LPBI 2.0 – Pay per Use

10.  LPBI Group runs FIVE ACADEMIC INTERNSHIPS as Certificate Programs: a One Year long or a One Semester long: Volunteer base offering Verifiable Certificates, as described in https://pharmaceuticalintelligence.com/certificate-1-year/

LPBI has Students and their education goals in mind:

  • We Offer esteemed Affiliation, Mentorship by Scientists
  • NEW skills development in NLP, ML, AI applications to Medical Text Analysis
  • Skills in Synthetic Biology for Drug Discovery
  • References and Resume paragraph on accomplishments and goals during the INTERNSHIP
  • Opportunity to contribute to Publications and Podcasting
  • Explorations of opportunities in Life Sciences in the US

Below, are listed the FIVE ACADEMIC INTERNSHIPS as Verifiable Certificate Programs, One year or One semester: Volunteer base

  1.  NLP – Medical Text Analysis
  2. Synthetic Biology in Drug Discovery targeting Galectins
  3. IT Projects and Administration of IP Asset Classes. we developed a Plan for SOPs for LPBI Group’s IT & Data Science Management Projects https://pharmaceuticalintelligence.com/2019-vista/summer-2019-plan-research-associates-tasks/

The Informations technology & systems of LPBI include:

  • Journal, Books, e-Proceedings & Tweet Collections, and
  • GALLERY of +6,200 Biological Images.
  • All the platforms: Authoring, publishing and portals. Business analytics for Internet platforms presence:
  • Twitter Analytics +1,100 followers of two handles and
  • LinkedIn ~8,000 1st degree connections +1, 200 endorsements of LPBI’s Founder, and 
  • LinkedIn Followers: +500 CEOs.

4.  BLOCKCHAIN Architecture Design: Interface to NLP. The powerful aspect is hydrating a knowledge graph with NLP inferences so that they can be used for DISCOVERY. Storing those inferences on a blockchain have the value of committing the NLP inferences to a blockchain for purposes of provenance. However, the very important part is The INFRASTRUCTURE behind BurstIQ which is NOT JUST A BLOCKCHAIN. NLP-Blockchain IT Infrastructure is needed. The NLP inferences are part of a knowledge graph database In BurstIQ case is a LifeGraph – the larger architecture of the system functionality [the voice of Erich G., Chief Architect, LPBI Blockchain Mission #2].

5.  Corporate Finance, Business Analytics and Financial Modeling using Statistics, Operations Research (OR) and Econometrics. Students in Economics, Finance, OR and MBA students seeking a Capstone project will gain unmatched experience and new skills.

For Valuation of its portfolio of IP assets and the Team:

LPBI is challenging professors of Economics and Finance at the top American Ten Business Schools to contain the above described LPBI’s stream of ten innovations into a Discount rate of Net Present Value Model for valuation of LPBI as a venture. 

Current management and the Founder believe that we need a non-institution acquisition process, namely, we need to “Go Direct” Go Direct – find an interested CEO for a vertical or horizontal integration into existing production.

Of NOTE

Critical Missions and New Competencies, 2020 and beyond

  • Addressing Information Market needs for Text Analysis with NLP and Deep Learning in Medicine, Life Sciences and Health Care
  • Development and application of a Content monetization system of the cutting edge Blockchain IT platform of a Transactions Network customized to implement NLP on several API layers of the Blockchain architecture is featured in a detailed description HERE and is representing work-in-progress for 2021-2022.
  • Drug Discovery using Synthetic Biology Software for inhibitors of Galectins.

Venture Type

  • LPBI is an Internet-based Media e-Scientific Publisher and Medical Text Analysis with Machine Learning and Content Monetization of existing digital products and for the to be produced digital products by Natural Language Processing (NLP)
  • NLP and Blockchain are cutting edge technologies [full flag implementation Blockchain is 5 years old!!].
  • When these two are combined together as LPBI 2.0 strategy states – a technological frontier for content monetization is born and it could be applied to any content, i.e., Legal, Environmental, Economics and others, not limited to pharmaceutical & medical which represent the LPBI pioneering case.

  • NOVELTY in methodologies, practice and digital artifacts is contained in 3.3 GIGA BYTES.
  • We launched a NEW Genre for Scientific Books: Bi-Lingual: English – Spanish with the NLP Results of the Text Analysis by NLP and Domain Knowledge Expert Interpretations in Text and in Sound. The eTOCs in Spanish Audio, NLP results Interpretation in English Audio and in Spanish Audio and Editorial in English Audio.
  • We will pursue a Joint effort with Dr. Raphael Nir in Drug-discovery targeting Galectins using Synthetic Biology software

2012-2020 – Milestones accomplished by 1.0 LPBI

for

Ten Intellectual Property Asset Classes

  1. Multi-authoring system not in use by any other website on WordPress.com – World LARGEST hosting company of independent websites. It was Dr. Lev-Ari’s idea to augment the functionality and usage of the infrastructure from single to a multi-author system.
  2. IP Asset Class I: 2MM e-Readers are recorded for the content on the Journal, +6,000 articles and 730 categories of research. The Curation Methodology was applied to +6,000 times in two versions: Original Curations and Scientific Reporting.
  3. IP Asset Class V: Gallery of Biological Images embedded in original text producing prior art images, a Gallery of 6,200 in the WordPress.com cloud. If NLP created ~10 new images per article then the gallery of initial 5,100 [prior to NLP graphs uploaded to the Gallery] will involve adding 60,000 new images as a result of the visualization output of Natural Language Processing deployment.
  4. IP Asset Class IV: Cloud-based Platforms and Portals. Composition of Methods: (a) Software code for 25 keywords extraction and running executables for statistical and Semantic NLP using Deep Learning algorithms. (b) Formats for Curations, (c) Formats for electronic Table Of Contents (eTOCs), (d) Role definition for Editors and Experts, Authors, Writers. (e) Template system for e-Proceedings, (f) Template system for Tweeting in real time at VOLUME [Case in Point: +200 tweets in 20 hours, 2019 World Medical Innovation Forum on AI in Medicine, organized by MGH and BWH, Ranked Influencer #2, #3, #4 by the Twitter.com Rating Agencies: symplur and NodeXL].
  5. IP Asset Class X: Luminary Podcasts with (a) Life Sciences Scholars at LPBI, and (b) a Podcast Library of 270 Interviews with Scientific Leaders
  6. IP Asset Class II: BioMed e-Series of 18 Volumes in Medicine and Life Sciences featuring +50,000 pages of thematic selections and expert interpretations FRONTIERS of the scientific inquiry in five specialties in Medicine and in several disciplines in the Life Sciences, Pharmaceutics and Health Care. LPBI’s e-Books pioneered the entrance in e-Scientific Publishing. In 6/2013 when we published the 1st book, Elsevier and John Wiley – DID NOT YET HAVE ANY e-BOOKS. Page downloads from LPBI e-books is +128,000. All Books on Amazon.com https://lnkd.in/ekWGNqA
  7. IP Asset Class VII: Amazon.com transfers every 90 days Royalties on book sales and Page downloads. The Pay per View option deters and has deleterious effects on selling books. Payments for page download deposited for authors are pennies per page, though, +128,000 pages were downloaded to date and a significant sum was collected by Amazon.com.
  8. IP Asset Class III: We have 70 e-Proceedings documents [60 by Aviva and 10 by Dr. Williams] and 36 Tweet collections [by Aviva]. 100 Documents representing e-Proceedings of 70 Top Conferences and 36 Tweet collections of the latest 36 Conference covered, 2014-2021. 100 volumes available for download.
  9. IP Asset Class IX: AKA as Intangible assets. This topic is elaborated in 1.0 LPBI Prospectus, 300 pps.
  10. IP Asset Class VIII: 2,650 subscribers to the website
  11. IP Asset Class VI: The Team of Experts in the Organization Chart, below. A revised organization chart to Include LPBI India is work-in-progress and will exhibit all the missions and the personnel assigned.

Organization Chart for LPBI’s Venture Structure

Workflow and Talent for LPBI USA and LPBI India

New_Org_chart_LPBI

2021-2025: 2.0 LPBI’s Four Missions and IT Infrastructure Plan:

INSERT HERE IT Projects been pursued

Recap the four missions briefly as LPBI’s exposition of the pipelines for 2021 -2025:

Mission #1:  NLP – Team in USA & India – Medical Text Analysis with NLP – on LPBI 3.3 Giga Bytes of Content. Statistical NLP and Deep Learning by Machine Learning using Wolfram Language for Biological Sciences

https://pharmaceuticalintelligence.com/2021-medical-text-analysis-nlp/

Mission #2:  Blockchain IT and NLP Processing API generating NLP visualization Products used by Knowledge Graphs stored in Graph Databases – Content monetization infrastructure B2B and B2C.

https://pharmaceuticalintelligence.com/blockchain-transactions-network/

Mission #3:  BioMed e-Books – Book Republishing in new GENRE – Bi-Lingual and Multimedia Audio Podcast for Books in the 18-e-Books in five e-Series: A,B,C,D,E

https://pharmaceuticalintelligence.com/2021/07/24/proposal-for-new-e-book-architecture-combining-a-bi-lingual-etocs-english-spanish-with-nlps-results-of-medical-text-analysis-series-b-genomics-volume-1-2-and-series-c-cancer-volume-1/

Mission #4:  Synthetic Biology Software: Drug discovery Galectins

https://pharmaceuticalintelligence.com/synthetic-biology-in-drug-discovery/

Dr. Lev-Ari is the Founder of 1.0 LPBI, 2012-2020 and 2.0 LPBI, 2021-2025

Earning a PhD at University of California, Berkeley in 1983 enabled Aviva to join the Top Tier Management Consulting industry. The World Think Tank, SRI International in Menlo Park, CA and head a Practice on Research and Advanced Analytics. Followed by Head of Research of the Economic and Decision Analysis Center (EDAC) at MITRE. Next, director level positions in Research at Perot Systems Corporation (PSC) and McGraw Hill, 1985 to 2004. Her work is mentioned in the Annual Reports of SRI International, 1987, and in PSC’s Annual Report, 1999.

  • It is noteworthy that Dr. Lev-Ari was a student at the Hebrew University in Jerusalem, 1970-1976 and a Research Associated at Technion, Israel Institute of Technology, 1977-1978, in preparation for doctoral studies at UC, Berkeley.

In the Healthcare Delivery Industry, 2005-2012, Aviva got the National Board of Nursing Registration in 1/2008. Jointly with her Prof. of Pharmacology, Dr. Lev-Ari developed a combination drug therapy concept for major cardiovascular events prevention. She was Supervisor of a Long Term Acute Care Hospital in Waltham, MA and was Clinical Nurse Manager of two units in Post Acute Facilities in Boston, Belmont and Canton, MA.

In 2012, Dr. Lev-Ari launched as Founder the Medical Media venture PharmaceuticalIntelligence.com 

Aviva Lev-Ari, PhD, RN is the inventor of the curation methodology for clinical interpretation of scientific findings

  • the inventor of the eTOCs format for the BioMed e-Series. As Editor-in-chief, architected the five e-Series: A,B,C,D,E and specified the book Titles.
  • Jointly, with Dr. Williams all the cover pages were designed for the 18 volumes.
  • the inventor One click e-Proceedings generation and the Tweeting template system
  • the inventor of the fusion of NLP and Blockchain, and

Of 6,080, under her name are 3,550 articles [Dashboard read on 8/1/2021]

Twelve Economic Segments for LPBI Group’s IP – Prospects for Transfer of Ownership

This list is repeated for reiteration that the technologies at LPBI are serving 12 verticals

https://pharmaceuticalintelligence.com/2019-vista/opportunities-map-in-the-acquisition-arena/

  1.     Holding Companies, Investment Bankers and Private Equity
  2.     Information Technology Companies – Health Care
  3.     Scientific Publishers
  4.     Big Pharma
  5.     Internet Health Care Media & Digital Health
  6.     Online Education
  7.     Health Insurance Companies & HMOs
  8.     Medical and Pharma Associations
  9.     Medical Education
  10.     Information Syndicators
  11.     Global Biotech & Pharmaceutical Conference Organizer
  12.     CRO & CRA

Financial Projections are in an Excel file with three spreadsheets:

  • 1.0 LPBI, 2012-2020 – AVAILABLE FOR MONETIZATION FOLLOWING INDEXING AND MIGRATION TO THE BLOCKCHAIN as soon as the platform will be up and running
  • 2.0 LPBI, 2021-2025 – NLP Proof-of-Concept in Phase 2 with Linguamatics was completed and presented on on 7/13/2021 to a potential Joint client of Linguamatics and LPBI. Forthcoming next meeting in 9/2021.
  • In-house, Wolfram algorithms applied on LPBI’s content: Journal articles and 18 e-Books in Medicine is ongoing. The Assignments are presented on 7/27/2021 UPDATE on https://pharmaceuticalintelligence.com/2021-medical-text-analysis-nlp/
  • Combined, 2012-2025 presents the Projected Financials for 1.0 and 2.0 LPBI

Two charts are presented, below.

  • The first exhibits the cumulative number of views 7/2013 – 6/2020, will be updated on 1/1/2022.
  • The second chart presents the Actual article views 4/2012 – 6/2020 and projected article views 2021-2025. Each view is equated to an article download at $30. Potential cumulative Journal revenues are presented on the Y axis: 2012-2020 base on actual data, 2021-2025 represent prediction.
  • Reference for the methods in use for the prediction is listed, below.

Source:

PharmaceuticalIntelligence.com Journal – Projecting the Annual Rate of Article Views

https://pharmaceuticalintelligence.com/vision/pharmaceuticalintelligence-com-journal-projecting-the-annual-rate-of-article-views/

Following the description of the accomplishments of 1.0 LPBI and the four missions of 2.0 LPBI, we are repeating here the Exit three Options seen by management.

The potential opportunities for ownership transfer need to consider

the Portfolio of TEN IP Asset Classes and FOUR missions for 2021-2025 and the TEAM

An inclusive Plan for three Exit Options are revisited:

  • Option 1,
  • Option 2: Version 1 and
  • Option 2: Version 2

Option 1:

Outright Sale of 10 IP assets created by 1.0 LPBI, 2021 – 2020.

Option 2:

Turnaround Version 1: A + B [Inorganic]

[A = Outright Sale of 10 IP assets]

AND

  1. [B = INORGANIC –  EXTERNAL management and EXTERNAL ownership for 2.0 strategy
  • Alliances in NLP Proof-of-Concept to be followed by scaling up to all content of four IP asset classes
  • Alliance in Blockchain Transactions Network for B2B & B2C. Status: design phase
  • Alliances in Content promotion in Spanish speaking countries and
  • Alliance in Synthetic Biology SW for targeted therapeutics in Drug Discovery

AND

The Team of Experts in the US and in India

Option 3:

Turnaround Version 2: Organic – “Equity” Sharing Buyout

[A = Buying out Aviva’s LION’s share] AND [B = Buying out Dr. Larry’s share]

AND

[C = ORGANIC – Continue 2.0 LPBI by LPBI INTERNAL management [SJW & JFM]] AND NEW EXTERNAL Ownership. The Right of First Refusal is offered INTERNALLY to 1.0 LPBI member(s) to take the helm of 2.0 LPBI]

AND

The Team of Experts in the US and in India

Opening and Closing Statement

Current management and the Founder believe that we need a non-institution acquisition process, namely, we need to “Go Direct”

Go Direct – find an interested CEO.

Read Full Post »

February 1, 2021 – We Celebrate 1,924,400 e-Readers, 6,000 Scientific Journal Articles, 7,525 Scientific Comments, A Journal Ontology of 728 Medical & Life Sciences Research Categories, 10,440 Tags, Top Article 17,300 Views, Top Author 487,500 Views on PharmaceuticalIntelligence.com

Reporter: Aviva Lev-Ari, PhD, RN

Update on 7/1/2021 by Srinivas Sriram and Abhisar Anand

2/1/2021 – 1,924,462 views
7/1/2021 – 2,003,639 views 

7,555 comments

Content

2/1/2021 – 6,001 Posts
7/1/2021 – 6,056 Posts

736 Categories

10,545 Tags

 

Top Articles by Views 2/1/2021 vs 7/1/2021

Top Posts for all days ending 2021-07-01 (Summarized)
Date of Production: 2021-07-01

Top Posts for all days ending 2021-02-01 (Summarized)

 

Top Authors by Views 2/1/2021 vs 7/1/2021

Top Authors for all days ending 2021-07-01 (Summarized)
Date of Production: 2021-07-01

All Time

Author   Views
2012pharmaceutical

 

Aviva Lev-Ari, PhD, RN

  486,733
larryhbern 356,793
sjwilliamspa 68,594
tildabarliya   68,093
Dr. Sudipta Saha 37,665
Dror Nir   37,564
Demet Sag, Ph.D., CRA, GCP 19,590
ritusaxena 17,170
Gail S Thornton 16,768
     
Irina Robu 9,861

Line Graph Depicting Top Authors Progression by Views Ending 2021-07-01
Date of Production: 2021-07-01

Top Authors for all days ending 2021-02-01 (Summarized)

All Time

Author   Views
2012pharmaceutical

 

Aviva Lev-Ari, PhD, RN

  463,371
larryhbern 342,084
tildabarliya   66,800
sjwilliamspa 66,203
Dror Nir   36,797
Dr. Sudipta Saha 35,862
Demet Sag, Ph.D., CRA, GCP 19,058
ritusaxena 17,007
Gail S Thornton 15,664
     
Irina Robu 9,019

Read Full Post »

One Possible Strategy for an Acquisition is via a Special Purpose Acquisition Company (SPAC)

Authors: Joel Shertok, PhD, Board Member and Aviva Lev-Ari, PhD, RN, Founder, LPBI Group, 1.0 & 2.0

 

UPDATED ON 3/18/2021

That seems to be confirmed by a recent study by Michael Klausner and Emily Ruan of Stanford University and Michael Ohlrogge of New York University. The authors look at blank-cheque firms that made acquisitions between January 2019 and June 2020. They find that, in 25% of cases, the sponsor’s payout exceeded 12% of post-merger equity, compared with a median stake of 7.7%.

They also conclude that some spacs deliver far worse returns for investors than others: companies that went public through the spac route fell in value by an average of 3% after three months, 12% after six months and by a third after 12 months. They lagged behind the wider market and even further behind an index of firms that listed via ipo.

However, about half the sample is made up of “high-quality” spacs, defined as those run by former Fortune 500 bosses or set up by large private-equity firms. These perform much better, outperforming ipos and the wider market over six months (though not over 12).

SOURCES

https://www.economist.com/finance-and-economics/2021/02/16/why-spacs-are-wall-streets-latest-craze

The SPAC Bubble May Burst—and Not a Day Too Soon

A Sober Look at SPACs

57 Pages Posted: 16 Nov 2020 Last revised: 6 Mar 2021

Michael Klausner

Stanford Law School; European Corporate Governance Institute (ECGI)

Michael Ohlrogge

New York University School of Law

Emily Ruan

affiliation not provided to SSRN

Date Written: October 28, 2020

Abstract

A Special Purpose Acquisition Company (“SPAC”) is a publicly listed firm with a two-year lifespan during which it is expected to find a private company with which to merge and thereby bring public. SPACs have been touted as a cheaper way to go public than an IPO. This paper analyzes the structure of SPACs and the costs built into their structure. We find that costs built into the SPAC structure are subtle, opaque, and far higher than has been previously recognized. Although SPACs raise $10 per share from investors in their IPOs, by the time the median SPAC merges with a target, it holds just $6.67 in cash for each outstanding share. We find, first, that for a large majority of SPACs, post-merger share prices fall, and second, that these price drops are highly correlated with the extent of dilution, or cash shortfall, in a SPAC. This implies that SPAC investors are bearing the cost of the dilution built into the SPAC structure, and in effect subsidizing the companies they bring public. We question whether this is a sustainable situation. We nonetheless propose regulatory measures that would eliminate preferences SPACs enjoy and make them more transparent, and we suggest alternative means by which companies can go public that retain the benefits of SPACs without the costs.

 

Keywords: SPAC, Securities Law

Klausner, Michael D. and Ohlrogge, Michael and Ruan, Emily, A Sober Look at SPACs (October 28, 2020). Yale Journal on Regulation, Forthcoming, Stanford Law and Economics Olin Working Paper No. 559, NYU Law and Economics Research Paper No. 20-48, Available at SSRN: https://ssrn.com/abstract=3720919 or http://dx.doi.org/10.2139/ssrn.3720919

 

UPDATED on 3/17/2021

Paul R. Milgrom

The Sveriges Riksbank Prize in Economic Sciences in Memory of Alfred Nobel 2020

Born: 20 April 1948, Detroit, MI, USA

Affiliation at the time of the award: Stanford University, Stanford, CA, USA

Prize motivation: “for improvements to auction theory and inventions of new auction formats.”

Prize share: 1/2

To cite this section
MLA style: Paul R. Milgrom – Facts – 2020. NobelPrize.org. Nobel Media AB 2021. Thu. 18 Mar 2021. <https://www.nobelprize.org/prizes/economics/2020/milgrom/facts/>

LECTURE by Paul R. Milgrom

https://www.nobelprize.org/prizes/economic-sciences/2020/milgrom/lecture/

To cite this section
MLA style: Robert B. Wilson – Interview. NobelPrize.org. Nobel Media AB 2021. Wed. 17 Mar 2021. <https://www.nobelprize.org/prizes/economic-sciences/2020/wilson/interview/>

Robert B. Wilson

The Sveriges Riksbank Prize in Economic Sciences in Memory of Alfred Nobel 2020

Born: 16 May 1937, Geneva, NE, USA

Affiliation at the time of the award: Stanford University, Stanford, CA, USA

Prize motivation: “for improvements to auction theory and inventions of new auction formats.”

Prize share: 1/2

To cite this section
MLA style: Robert B. Wilson – Facts – 2020. NobelPrize.org. Nobel Media AB 2021. Thu. 18 Mar 2021. <https://www.nobelprize.org/prizes/economics/2020/wilson/facts/>

 

UPDATED on 2/5/2021

SPAC growth has multiplied faster than the COVID-19 virus contagion.  In fact, the pandemic frightened many companies who were contemplating an IPO in 2020.  A SPAC is a safer way to get to an IPO during market and economic hardships.  Think of it as a merger behind closed doors rather than under the magnifying glass of the SEC, investors, creditors, etc.  70% of all money raised through public offerings in January 2021 were SPACs. Per the graph, 2020 saw $82B poured into SPACs.  The single month of January 2021 saw more than 96 SPACs raise $20B.  The US is now seeing 5 new SPACs a day!

“Many of the 287 SPACs currently hunting for targets are looking for deals in hot sectors such as technology or electric vehicles, according to figures from data provider SPAC Research. Last week, six new SPACs launched: Queen’s Gambit Growth Capital —a company led entirely by women that shares a name with an opening sequence in chess and a popular show on Netflix —Legato Merger, Gores Metropoulos II, Oyster Enterprises Acquisition, TZP Strategies Acquisition and FoxWayne Enterprises Acquisition. Eight more went public on Friday”. Amirth Ramkuma / Wall Street Journal

UPDATED on 2/2/2021

Blank Check Companies’ Hunt For Innovative Medtech Start-Ups To Heat Up Further, Experts Predict

Healthcare SPAC Mergers – Overview

Chart

Source: Chardan, FactSet, CapIQ, latest close as of 01/25/2021

Joseph Hernandez, founder and CEO of Blue Water Acquisition Corp., a SPAC that is currently looking for an acquisition target in the health care space, also expects a lot more deal flow in medtech, particularly in artificial intelligence, telemedicine, cardiology, joint replacements, diagnostics and genomics.

JOSEPH HERNANDEZ, FOUNDER AND CEO, Blue Water Acquisition Corp.

“Medtechs are often undervalued in the market, but I think if you look at their risk profile, they are usually less risky than biotech companies because you usually have a product,” Hernandez told Medtech Insight.

Blue Water Acquisition announced on 15 December it raised $50m by offering 5 million units at $10. Each unit consists of one share of common stock and one warrant exercisable at $11.50. The underwriter, Maxime Group, exercised its over-allotment option, resulting in $57.5m raised.

“We have been a free-trading company for a little bit over 30 days and I can tell you we’ve seen a large number of deals – in excess of 40 deals we’ve looked at [at] this point – and continue to get deal flow here on a daily basis,” Hernandez said. Though he feels that the smaller size of the SPAC, which puts it at an acquisition target range of roughly $75-$240m, puts it in the “sweet spot.”

“There’s not a lot of players in this acquisition spectrum,” he said. The majority of deals have been on the larger side, where there are more SPACs competing for the same private companies.

Karim Anani, EY Americas Transactions Accounting Advisory Leader and EY Capital Markets Partner advising companies on strategic transactions, also expects the SPACs craze to continue ramping up in 2021.

“We’re also starting to see increased deal sizes, so the valuations and the size of the companies that SPACs are looking to merge with in the medtech space are increasing as we progress through 2020 and go into 2021,” Anani told Medtech Insight. “The amount of capital, if you consider general SPACs and what is identified for this industry, is probably $10-$14bn – it just depends how you want to cut the data.”

SPACs Bubble?

Goldman Sachs Group Inc. CEO David Solomon, among others, have expressed concerns about the sustainability of SPACs. Solomon warned in the company’s call in January that the flurry of SPACs is not sustainable in the medium-term. Goldman Sachs is among the banks benefitting from the boom.

Grossman also foresees that there will be “slowing of the pace,” noting that there are about 250 SPACs out there.

“Once it gets to 300 or 400, it starts to get crowded in each of the different spaces and there’s only a limited number of opportunities for public-ready companies,” he said. Nevertheless, he believes that 2021 will be an interesting year.

“I think you’re going to see a lot of innovative companies go public, especially in medtech.”

SOURCE

https://medtech.pharmaintelligence.informa.com/MT143415/Blank-Check-Companies-Hunt-For-Innovative-Medtech-StartUps-To-Heat-Up-Further-Experts-Predict?vid=Pharma&processId=bbaaf314-e3b9-4ed1-8631-b85f7773183b

 

1/20/2021

Overview of Leaders in Pharmaceutical Business Intelligence (LPBI)

ACQUISITION STRATEGIES AND INVESTMENT NEEDS

 

LPBI was founded by Dr Aviva Lev-Ari, RN, PhD in 2012 and developed since then to Present.

During the period 2012-2020 – LPBI developed a vast Intellectual Property portfolio of several IP Assets (LPBI 1.0):

  • 2MM e-Readers,
  • 6000 Journal articles,
  • 18 e-Books in Medicine,
  • 100 e-Proceedings & Tweet Collections and
  • 5000 Biological images

Starting in 2021, LPBI will evolve into a new entity building on LPBI 1.0 IP Portfolio, designated LPBI 2.0:

See below links for more information.

LPBI 2.0 is pursuing:

  1. Medical Text Analysis NLP, ML-AI on our content created 2012-2020
  2. Content Monetization on Blockchain: existing digital products, and ML products

LPBI is seeking potential acquirers in both Israel and the United States, as LPBI 2.0 requires both an acquirer and investor/investment to realize its strategies. This will involve the transfer of ownership of an IP Portfolio consisting of over 3.3 Gigabytes of cloud-based English text and associated biological images.

The projected acquisition will also entail new management of the IP Portfolio consisting of both 1 and 2 strategies, above, along with a team of ten Experts in Medicine and Life Sciences.

We feel that realizing these activities will require either:

  • An existing company able to execute an M&A strategy, or
  • An investor/acquirer to convert LPBI to a new ownership, assuming control of the IP and the LPBI Team.

Investment will be necessary to support these strategies:

A. The conversion of our content via Natural Language Processing (NLP) and Machine Learning (ML) /Artificial Intelligence (AI) into the corresponding graphics along with its interpretation by experts.

  • Scaling up to all contents of LPBI 1.0 IP Portfolio: Journal articles, books, e-Proceedings, Biological Images

B. The implementation of the Blockchain Transaction Network, necessary for secure monetization of LPBI existing content:

  • Journal articles, books, e-Proceedings, Biological Images
  • New products generated by NLP (hyper-graphs and expert interpretation),
  • B2C – a Digital Store in a Healthcare Digital Marketplace, and
  • B2B – installations in Big Pharma and Healthcare Insurers involve implementation of the customized design of a Blockchain transaction IT infrastructure:

These include IT design, which represents the first ever combined IT infrastructure for NLP and Blockchain transaction network:

  • Recommendation Engine,
  • Smart Contracts,
  • Permissions,
  • Immutable ledger

C. Addition operations requiring investment:

  • Original data migration from an Authoring cloud to a Transaction cloud.
  • Hosting a Digital Store in an existing Healthcare Digital Marketplace for B2C
  • B2B special installations and development of consultancy services
  • Content promotion campaigns

One possible strategy for an acquisition is via a Special Purpose Acquisition Company (SPAC)

  • Discussion of this strategy: Date TBD

 

Additional Background Sources:

LPBI 1.0:

https://pharmaceuticalintelligence.com/2019-vista/

LPBI 2.0:

https://pharmaceuticalintelligence.com/vision/

Projections

https://pharmaceuticalintelligence.com/vision/pharmaceuticalintelligence-com-journal-projecting-the-annual-rate-of-article-views/

Portfolio of 10 Intellectual Property Asset Classes

https://pharmaceuticalintelligence.com/2019-vista/

Six Strategies, 2021-2025

https://pharmaceuticalintelligence.com/vision/

The Opportunities Map

https://pharmaceuticalintelligence.com/2019-vista/opportunities-map-in-the-acquisition-arena/

The Team

https://pharmaceuticalintelligence.com/knowledge-portals-system-kps/

Read Full Post »

Potential interest in LPBI Group’s BioMed e-Series 

Advisor: Conxa Catot · BDM, ex-Elsevier

 

Conxa Catot · BDM
CONTENT ED NET
conxa.catot@contentednet.com
+34 639 357 643
Avda. Josep Tarradellas, 8, 4-4

08029 Barcelona, Spain

 

LPBI Group’s BioMed e-Series – 18 Volumes in Medicina and Life Sciences

Series A: e-Books on Cardiovascular Diseases

                    6 Volumes

Series B: Frontiers in Genomics Research

                    2 Volumes

Series C: e-Books on Cancer & Oncology

                    2 Volumes

Series D: e-Books on BioMedicine – Metabolomics, Immunology, Infectious Diseases, Reproductive Genomic Endocrinology

                    4 Volumes

Series E: Patient-Centered Medicine – LINKS to e-Books & Cover Pages for Volumes 1,2,3,4

                    4 Volumes

Advice offered by Conxa Catot · BDM, ex-Elsevier

 

  • Panamericana to offer the ebooks

https://www.medicapanamericana.com/

  • Springer Nature

https://www.springernature.com/la

  • Exlibris Group was purchased by Proquest

https://exlibrisgroup.com/

  • Proquest

https://about.proquest.com/

Ana Neira ana.neira@proquest.com and offer your ebooks and contents; she will forward you to the right contact in case they have interest.

  • ebook platform from Proquest

https://ebookcentral.proquest.com/

 

Read Full Post »

e-Voices Podcasting by LPBI: Celebrating Podcast #3 in an Audio Library on leading Scientists and Key Opinion Leaders in Biological Sciences

Authors: Aviva Lev-Ari, PhD, RN

 

2.0 LPBI had published today its third Podcast uploaded to our Cloud at WordPress.com

https://pharmaceuticalintelligence.com/audio-podcasts/

  • Our three podcasts are about the careers of Leaders in Science and Medicine featured in LPBI’s emerging PODCAST LIBRARY, under development.
  • Podcasting Library represents an initiative of Dr. Stephen J. Williams, PhD and Aviva Lev-Ari, PhD, RN as expressing on 1/25/2016:

Launching LPBI’s, Fourth Line of Business (D): FIVE Podcasts – Audio Series in BioMed

Curator: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2016/01/25/launching-lpbis-fourth-line-of-business-d-five-podcast-audio-series-in-biomed/

  • Since 2019 this initiative is under the leadership of Gail S. Thornton
  • Audio Podcasts represent Strategy #3 in 2020-2021 Vision for 2.0 LPBI
  • Development Plan for e-VOICES Podcasting, 2019 – 2021* is presented in

https://pharmaceuticalintelligence.com/audio-podcasts/

 

 Interviewer
Interviewees
Topic
yr
media
2019

&

2020
 
 
 
Gail S.
Thornton
Dr. Stephen J.
Williams,
Dr. Irina Robu &
Dr. Aviva Lev-Ari
3D BioPrinting in
Medicine
’19
Audio
Gail S.
Thornton
Prof. Feldman
Evolution Biology
and
Population Genetics
’20
Audio
Gail S.
Thornton
Dr. Larry H.
Bernstein,
MD, FCAP
Life Memoirs in
Clinical
Pathology 
’20
Audio
Narrator:
Dr. S.J. Williams
Gail S.
Thornton
Dr. Sudipta Saha
Research in
Reproductive
Technology
’20
Audio
2021
 Gail S.
Thornton
Dr. Justin D.
Pearlman,
MD, PhD
Cardiac Imaging –
Evolution of
Diagnostic
Methods
’21
Audio
Gail S.
Thornton
Dr. Raphael Nir
From Big Pharma to
Biotech
Entrepreneurship
’21
Audio
Gail S.
Thornton
Dr. Meg Baker
GlycoBiology in
Practice
’21
Audio
Gail S.
Thornton
Dr. Ofer Markman
Memories of
Procognia
’21
Audio
Gail S.
Thornton
Dr. Irina Robu
AI & Tissue
Engineering
’21
Audio
Gail S.
Thornton
Dr. Williams
Preferably 3rd 
party
interviewer
sourced
by Gail
AI & Genomics 
’21
Audio
Gail S.
Thornton
Dr. Aviva Lev-Ari
Preferably 3rd 
party
interviewer
sourced
by Gail
Curation & ML
’21
Audio

 

PODCAST #3:

Dear Dr. Saha,

I enjoyed very much the Podcast uploaded today on your Career in Biological Sciences.

Learning about your career by watching the Podcast was a special experience in comparison to reading your CV in 2012 and inviting you to join the Team of EAWs at LPBI.

  • I am so glad that I invited you then and had uploaded your CV to our Cloud on September 9, 2012 at 8:02 pm 
  • I am very happy that we have completed in BioMed e-Series: Volume #17 on Reproductive Genomic and Endocrinology 
  • I have initiated and launched that volume as an opportunity to put together the majority of your contributions in this domain on our Journal

Series D: e-Books on BioMedicine – Metabolomics, Immunology, Infectious Diseases, Reproductive Genomic Endocrinology

Volume Four: Human Reproductive System, Genomic Endocrinology and Cancer Types

https://pharmaceuticalintelligence.com/biomed-e-books/series-d-e-books-on-biomedicine/series-d-volume-4-human-reproductive-system-genomic-endocrinology-and-cancer-types/

Book Structure

 

Sudipta Saha, PhD

Larry H. Bernstein,

MD, FCAP

Stephen J. 

Williams, PhD

Aviva

Lev-Ari, PhD, RN

TOTAL

# Articles

24

37

5

20

Enjoy the podcast

###

PODCAST #2:

Dear Dr. Larry,

Your PODCAST represents an amazing career in Medicine

I have uploaded your CV on Sep 9, 2012 at 19:59 pm

Since 2012 till the end of 2016 – you were 

  • LPBI’s Chief Scientific Officer, 
  • Author/Curator of 1,400 articles 
  • Content Consultant on 4 of our 5 e-Book e-Series 
  • Editor of 15 e-Books of our 17 e-Books
  • Single Author of 3 of the 17 e-Books

I am indebted to all your contributions to 1.0 LPBI’s Portfolio of Intellectual Properties

Enjoy the podcast!

Please click here to listen to an expanded life and times of Larry H. Bernstein, M.D. FCAP

###

 

PODCAST #1:

Dear Prof. Feldman,

Your podcast is carrying the voice of an amazing Scientist in Evolution Biology, 

among the top 10 World renown contributors to this field

 

I have uploaded your CV on  September 9, 2012 at 9:38 am

  • We met in 9/1987 when I was a newly minted Berkeley, PhD working at SRI International and you were and still are at Stanford University
  • You followed my career since then, ~35 years
  • I thank you for your contributions to LPBI and your support of my initiatives

Enjoy the podcast!

Future podcasts will feature scientists, clinicians and researchers behind some of the most exciting medical and scientific advances in the world. 

Podcast 2020-02-14 Gail Thornton Interviews Prof. Marcus Feldman by Leaders in Pharmaceutical Business Intelligence

Read Full Post »

Older Posts »